Phase II dose-ranging trial of RCH 01, an autologous hair cell product, for androgenetic alopecia.
Phase of Trial: Phase II
Latest Information Update: 29 Apr 2015
At a glance
- Drugs RCH 01 (Primary)
- Indications Male pattern baldness
- Focus Therapeutic Use
- 29 Apr 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jun 2015, based on a RepliCel Life Sciences media release.
- 13 Feb 2013 New trial record